Hanrui Zheng
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Cost-Effectiveness of Tarlatamab in the Second-Line Treatment of Refractory Small Cell Lung Cancer From a US Perspective.
Journal: Clinical Medicine Insights. Oncology
Published: August 28, 2025
Cost-effectiveness analysis of glofitamab versus rituximab for relapsed or refractory diffuse large B-cell lymphoma patients in China.
Journal: International journal of clinical pharmacy
Published: February 19, 2025
Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients.
Journal: Frontiers in immunology
Published: February 05, 2024
Cost-effectiveness analysis of fruquintinib in Chinese patients with refractory metastatic colorectal cancer.
Journal: International journal of clinical pharmacy
Published: November 07, 2023
Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma.
Journal: Frontiers in oncology
Published: May 04, 2023
Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
Journal: Frontiers in pharmacology
Published: January 16, 2023
Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective.
Journal: Frontiers in pharmacology
Published: December 28, 2022
Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04.
Journal: Frontiers in public health
Published: September 21, 2022
Corrigendum: Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma.
Journal: Frontiers in public health
Published: June 10, 2022
Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma.
Journal: Frontiers in public health
Published: December 17, 2021
Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
Journal: Frontiers in public health
Published: October 06, 2021
Last Updated: 09/26/2026